Black Diamond Therapeutics (BDTX) Competitors

$3.66 +0.07 (+1.81%)

As of 02:45 PM Eastern

BDTX vs. TLRY, CLYM, CTMX, CRMD, and ARVN

Should you buy Black Diamond Therapeutics stock or one of its competitors? MarketBeat compares Black Diamond Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Black Diamond Therapeutics include Tilray Brands (TLRY), Climb Bio (CLYM), CytomX Therapeutics (CTMX), CorMedix (CRMD), and Arvinas (ARVN). These companies are all part of the "pharmaceutical products" industry.

How does Black Diamond Therapeutics compare to Tilray Brands?

Tilray Brands (NASDAQ:TLRY) and Black Diamond Therapeutics (NASDAQ:BDTX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, earnings, media sentiment, analyst recommendations, institutional ownership and profitability.

9.4% of Tilray Brands shares are held by institutional investors. Comparatively, 95.5% of Black Diamond Therapeutics shares are held by institutional investors. 0.8% of Tilray Brands shares are held by insiders. Comparatively, 9.3% of Black Diamond Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Tilray Brands has a beta of 1.94, suggesting that its stock price is 94% more volatile than the broader market. Comparatively, Black Diamond Therapeutics has a beta of 3.34, suggesting that its stock price is 234% more volatile than the broader market.

Black Diamond Therapeutics has a net margin of 0.00% compared to Tilray Brands' net margin of -156.51%. Tilray Brands' return on equity of -3.31% beat Black Diamond Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tilray Brands	-156.51%	-3.31%	-2.42%
Black Diamond Therapeutics	N/A	-30.18%	-23.91%

Black Diamond Therapeutics has lower revenue, but higher earnings than Tilray Brands. Black Diamond Therapeutics is trading at a lower price-to-earnings ratio than Tilray Brands, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tilray Brands	$821.31M	0.78	-$2.19B	-$13.65	N/A
Black Diamond Therapeutics	$70M	3.00	$22.37M	-$0.77	N/A

In the previous week, Tilray Brands had 4 more articles in the media than Black Diamond Therapeutics. MarketBeat recorded 5 mentions for Tilray Brands and 1 mentions for Black Diamond Therapeutics. Tilray Brands' average media sentiment score of 0.41 beat Black Diamond Therapeutics' score of 0.00 indicating that Tilray Brands is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tilray Brands	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Black Diamond Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Tilray Brands currently has a consensus target price of $11.50, suggesting a potential upside of 109.66%. Black Diamond Therapeutics has a consensus target price of $10.00, suggesting a potential upside of 172.85%. Given Black Diamond Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Black Diamond Therapeutics is more favorable than Tilray Brands.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tilray Brands	1 Sell rating(s)	4 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.25
Black Diamond Therapeutics	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.70

Summary

Black Diamond Therapeutics beats Tilray Brands on 11 of the 17 factors compared between the two stocks.

How does Black Diamond Therapeutics compare to Climb Bio?

Black Diamond Therapeutics (NASDAQ:BDTX) and Climb Bio (NASDAQ:CLYM) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, profitability, dividends, analyst recommendations, risk, media sentiment and institutional ownership.

Black Diamond Therapeutics has higher revenue and earnings than Climb Bio. Climb Bio is trading at a lower price-to-earnings ratio than Black Diamond Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Black Diamond Therapeutics	$70M	3.00	$22.37M	-$0.77	N/A
Climb Bio	N/A	N/A	-$59.85M	-$0.78	N/A

Black Diamond Therapeutics' return on equity of -30.18% beat Climb Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Black Diamond Therapeutics	N/A	-30.18%	-23.91%
Climb Bio	N/A	-31.45%	-30.39%

Black Diamond Therapeutics has a beta of 3.34, meaning that its share price is 234% more volatile than the broader market. Comparatively, Climb Bio has a beta of 0.02, meaning that its share price is 98% less volatile than the broader market.

In the previous week, Climb Bio had 3 more articles in the media than Black Diamond Therapeutics. MarketBeat recorded 4 mentions for Climb Bio and 1 mentions for Black Diamond Therapeutics. Climb Bio's average media sentiment score of 0.56 beat Black Diamond Therapeutics' score of 0.00 indicating that Climb Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Black Diamond Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Climb Bio	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

95.5% of Black Diamond Therapeutics shares are owned by institutional investors. Comparatively, 69.8% of Climb Bio shares are owned by institutional investors. 9.3% of Black Diamond Therapeutics shares are owned by company insiders. Comparatively, 2.6% of Climb Bio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Black Diamond Therapeutics currently has a consensus price target of $10.00, suggesting a potential upside of 172.85%. Climb Bio has a consensus price target of $20.30, suggesting a potential upside of 84.39%. Given Black Diamond Therapeutics' higher probable upside, equities research analysts plainly believe Black Diamond Therapeutics is more favorable than Climb Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Black Diamond Therapeutics	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.70
Climb Bio	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	3 Strong Buy rating(s)	3.08

Summary

Black Diamond Therapeutics beats Climb Bio on 10 of the 15 factors compared between the two stocks.

How does Black Diamond Therapeutics compare to CytomX Therapeutics?

Black Diamond Therapeutics (NASDAQ:BDTX) and CytomX Therapeutics (NASDAQ:CTMX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, analyst recommendations, valuation, media sentiment, institutional ownership and profitability.

Black Diamond Therapeutics has a net margin of 0.00% compared to CytomX Therapeutics' net margin of -166.40%. Black Diamond Therapeutics' return on equity of -30.18% beat CytomX Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Black Diamond Therapeutics	N/A	-30.18%	-23.91%
CytomX Therapeutics	-166.40%	-36.61%	-28.02%

In the previous week, CytomX Therapeutics had 2 more articles in the media than Black Diamond Therapeutics. MarketBeat recorded 3 mentions for CytomX Therapeutics and 1 mentions for Black Diamond Therapeutics. CytomX Therapeutics' average media sentiment score of 0.50 beat Black Diamond Therapeutics' score of 0.00 indicating that CytomX Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Black Diamond Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
CytomX Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Black Diamond Therapeutics has a beta of 3.34, indicating that its share price is 234% more volatile than the broader market. Comparatively, CytomX Therapeutics has a beta of 2.18, indicating that its share price is 118% more volatile than the broader market.

Black Diamond Therapeutics presently has a consensus price target of $10.00, suggesting a potential upside of 172.85%. CytomX Therapeutics has a consensus price target of $12.10, suggesting a potential upside of 220.53%. Given CytomX Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe CytomX Therapeutics is more favorable than Black Diamond Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Black Diamond Therapeutics	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.70
CytomX Therapeutics	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.91

95.5% of Black Diamond Therapeutics shares are held by institutional investors. Comparatively, 67.8% of CytomX Therapeutics shares are held by institutional investors. 9.3% of Black Diamond Therapeutics shares are held by insiders. Comparatively, 6.6% of CytomX Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Black Diamond Therapeutics has higher earnings, but lower revenue than CytomX Therapeutics. CytomX Therapeutics is trading at a lower price-to-earnings ratio than Black Diamond Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Black Diamond Therapeutics	$70M	3.00	$22.37M	-$0.77	N/A
CytomX Therapeutics	$76.20M	8.43	-$17.37M	-$0.41	N/A

Summary

Black Diamond Therapeutics and CytomX Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Black Diamond Therapeutics compare to CorMedix?

CorMedix (NASDAQ:CRMD) and Black Diamond Therapeutics (NASDAQ:BDTX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, risk, institutional ownership, valuation, analyst recommendations, dividends and media sentiment.

CorMedix has a beta of 1.46, meaning that its share price is 46% more volatile than the broader market. Comparatively, Black Diamond Therapeutics has a beta of 3.34, meaning that its share price is 234% more volatile than the broader market.

34.2% of CorMedix shares are held by institutional investors. Comparatively, 95.5% of Black Diamond Therapeutics shares are held by institutional investors. 3.5% of CorMedix shares are held by company insiders. Comparatively, 9.3% of Black Diamond Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

CorMedix has higher revenue and earnings than Black Diamond Therapeutics. Black Diamond Therapeutics is trading at a lower price-to-earnings ratio than CorMedix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CorMedix	$311.71M	2.01	$163.05M	$2.13	3.74
Black Diamond Therapeutics	$70M	3.00	$22.37M	-$0.77	N/A

CorMedix presently has a consensus target price of $15.00, suggesting a potential upside of 88.09%. Black Diamond Therapeutics has a consensus target price of $10.00, suggesting a potential upside of 172.85%. Given Black Diamond Therapeutics' higher probable upside, analysts clearly believe Black Diamond Therapeutics is more favorable than CorMedix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CorMedix	0 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.75
Black Diamond Therapeutics	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.70

CorMedix has a net margin of 45.25% compared to Black Diamond Therapeutics' net margin of 0.00%. CorMedix's return on equity of 45.57% beat Black Diamond Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CorMedix	45.25%	45.57%	24.76%
Black Diamond Therapeutics	N/A	-30.18%	-23.91%

In the previous week, CorMedix had 16 more articles in the media than Black Diamond Therapeutics. MarketBeat recorded 17 mentions for CorMedix and 1 mentions for Black Diamond Therapeutics. CorMedix's average media sentiment score of 0.82 beat Black Diamond Therapeutics' score of 0.00 indicating that CorMedix is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CorMedix	7 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Black Diamond Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

CorMedix beats Black Diamond Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Black Diamond Therapeutics compare to Arvinas?

Arvinas (NASDAQ:ARVN) and Black Diamond Therapeutics (NASDAQ:BDTX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, earnings, risk, dividends, media sentiment, institutional ownership, analyst recommendations and profitability.

Arvinas presently has a consensus price target of $14.69, suggesting a potential upside of 59.02%. Black Diamond Therapeutics has a consensus price target of $10.00, suggesting a potential upside of 172.85%. Given Black Diamond Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Black Diamond Therapeutics is more favorable than Arvinas.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arvinas	3 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.36
Black Diamond Therapeutics	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.70

Black Diamond Therapeutics has lower revenue, but higher earnings than Arvinas. Black Diamond Therapeutics is trading at a lower price-to-earnings ratio than Arvinas, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arvinas	$262.60M	2.27	-$80.80M	-$3.32	N/A
Black Diamond Therapeutics	$70M	3.00	$22.37M	-$0.77	N/A

Arvinas has a beta of 1.79, meaning that its stock price is 79% more volatile than the broader market. Comparatively, Black Diamond Therapeutics has a beta of 3.34, meaning that its stock price is 234% more volatile than the broader market.

95.2% of Arvinas shares are held by institutional investors. Comparatively, 95.5% of Black Diamond Therapeutics shares are held by institutional investors. 7.3% of Arvinas shares are held by insiders. Comparatively, 9.3% of Black Diamond Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Black Diamond Therapeutics has a net margin of 0.00% compared to Arvinas' net margin of -247.54%. Black Diamond Therapeutics' return on equity of -30.18% beat Arvinas' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arvinas	-247.54%	-44.38%	-28.38%
Black Diamond Therapeutics	N/A	-30.18%	-23.91%

In the previous week, Arvinas had 11 more articles in the media than Black Diamond Therapeutics. MarketBeat recorded 12 mentions for Arvinas and 1 mentions for Black Diamond Therapeutics. Black Diamond Therapeutics' average media sentiment score of 0.00 beat Arvinas' score of -0.19 indicating that Black Diamond Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arvinas	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Black Diamond Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Black Diamond Therapeutics beats Arvinas on 13 of the 17 factors compared between the two stocks.

Get Black Diamond Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BDTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BDTX vs. The Competition

Export

Metric	Black Diamond Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$211.15M	$3.35B	$6.33B	$12.33B
Dividend Yield	N/A	2.32%	2.80%	5.36%
P/E Ratio	-4.79	18.89	20.88	25.51
Price / Sales	3.00	279.14	520.50	73.06
Price / Cash	5.69	125.35	43.18	55.00
Price / Book	2.01	6.90	10.01	7.03
Net Income	$22.37M	$24.18M	$3.54B	$334.92M
7 Day Performance	28.15%	0.77%	0.38%	-0.40%
1 Month Performance	16.35%	-0.38%	-0.02%	1.07%
1 Year Performance	80.54%	63.37%	35.07%	34.65%

Black Diamond Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BDTX Black Diamond Therapeutics	2.7023 of 5 stars	$3.67 +1.8%	$10.00 +172.9%	+65.9%	$211.15M	$70M	N/A	90	Analyst Downgrade High Trading Volume
TLRY Tilray Brands	3.1729 of 5 stars	$5.18 -2.6%	$11.50 +122.0%	+19.5%	$620.04M	$821.31M	N/A	2,842
CLYM Climb Bio	3.2818 of 5 stars	$9.88 -8.5%	$20.30 +105.5%	+748.4%	$618.41M	N/A	N/A	9
CTMX CytomX Therapeutics	3.0481 of 5 stars	$3.50 -3.0%	$12.78 +265.1%	+80.6%	$614.37M	$76.20M	N/A	170	Analyst Upgrade
CRMD CorMedix	3.3214 of 5 stars	$7.91 +4.8%	$15.00 +89.6%	-38.1%	$592.24M	$400.05M	3.71	30	Earnings Report Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BDTX) was last updated on 5/21/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Black Diamond Therapeutics (BDTX) Competitors

BDTX vs. TLRY, CLYM, CTMX, CRMD, and ARVN

How does Black Diamond Therapeutics compare to Tilray Brands?

Summary

How does Black Diamond Therapeutics compare to Climb Bio?

Summary

How does Black Diamond Therapeutics compare to CytomX Therapeutics?

Summary

How does Black Diamond Therapeutics compare to CorMedix?

Summary

How does Black Diamond Therapeutics compare to Arvinas?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BDTX vs. The Competition

Black Diamond Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Black Diamond Therapeutics (BDTX) Competitors

BDTX vs. TLRY, CLYM, CTMX, CRMD, and ARVN

How does Black Diamond Therapeutics compare to Tilray Brands?

Do insiders and institutionals hold more shares of TLRY or BDTX?

Which has more volatility & risk, TLRY or BDTX?

Is TLRY or BDTX more profitable?

Which has preferable earnings and valuation, TLRY or BDTX?

Does the media refer more to TLRY or BDTX?

Do analysts recommend TLRY or BDTX?

Summary

How does Black Diamond Therapeutics compare to Climb Bio?

Which has preferable valuation & earnings, BDTX or CLYM?

Is BDTX or CLYM more profitable?

Which has more risk & volatility, BDTX or CLYM?

Does the media refer more to BDTX or CLYM?

Do insiders & institutionals have more ownership in BDTX or CLYM?

Do analysts prefer BDTX or CLYM?

Summary

How does Black Diamond Therapeutics compare to CytomX Therapeutics?

Is BDTX or CTMX more profitable?

Does the media prefer BDTX or CTMX?

Which has more volatility & risk, BDTX or CTMX?

Do analysts rate BDTX or CTMX?

Do institutionals and insiders have more ownership in BDTX or CTMX?

Which has higher earnings & valuation, BDTX or CTMX?

Summary

How does Black Diamond Therapeutics compare to CorMedix?

Which has more risk & volatility, CRMD or BDTX?

Do institutionals and insiders hold more shares of CRMD or BDTX?

Which has preferable earnings & valuation, CRMD or BDTX?

Do analysts recommend CRMD or BDTX?

Is CRMD or BDTX more profitable?

Does the media refer more to CRMD or BDTX?

Summary

How does Black Diamond Therapeutics compare to Arvinas?

Do analysts recommend ARVN or BDTX?

Which has stronger valuation & earnings, ARVN or BDTX?

Which has more risk and volatility, ARVN or BDTX?

Do institutionals & insiders hold more shares of ARVN or BDTX?

Is ARVN or BDTX more profitable?

Does the media refer more to ARVN or BDTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BDTX vs. The Competition

Black Diamond Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools